Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca's Imfinzi combination fails advanced lung cancer study

Published 21/08/2019, 10:18
Updated 21/08/2019, 10:18
© Reuters. The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

© Reuters. The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

(Reuters) - AstraZeneca (L:AZN) said on Wednesday a combination treatment including its lung cancer drug Imfinzi failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations.

The clinical trial, called NEPTUNE, was testing Imfinzi along with tremelimumab and comparing the combination to platinum-based chemotherapy to treat patients whose cancer had spread to other parts of the body.

London-listed AstraZeneca said though the trial involved a wide range of patients, the primary group being tested had high levels of mutations in their DNA.

The combination treatment did not meet the main goal of improving overall survival in the primary group, the company said.

Mutations in tumours are measured using a system called tumour mutational burden (TMB) and the primary group had TMB of 20 or more.

Imfinzi belongs to the immunotherapy class of treatments that boost the body's own immune system to fight cancer, and tumours with high levels of TMB may be more visible to the immune system.

Rival immunotherapies include Bristol-Myers Squibb's (N:BMY) Opdivo.

NSCLC accounts for up to 85% of lung cancers, by far the leading cause of cancer death among men and women, according to the American Cancer Society.

© Reuters. The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

(This story corrects paragraph two to remove reference to tremelimumab as 'FDA-approved')

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.